Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
Mahmoud BarbarawiBabikir KheiriYazan ZayedInderdeep GakhalAhmad Al-AbdouhOwais BarbarawiLaith RashdanFatima RizkGhassan BachuwaMohammad Luay AlkotobPublished in: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2019)
Aspirin use in primary prevention has resulted in a lower incidence of MACE and MI without significantly effecting cerebrovascular events. However, aspirin was associated with a higher bleeding risk. Use of aspirin as a means of primary prevention should be thoroughly discussed with patients and pursued based on the risk of cardiovascular disease while also considering bleeding risk.
Keyphrases
- low dose
- cardiovascular events
- cardiovascular disease
- antiplatelet therapy
- end stage renal disease
- ejection fraction
- anti inflammatory drugs
- atrial fibrillation
- newly diagnosed
- chronic kidney disease
- systematic review
- peritoneal dialysis
- type diabetes
- prognostic factors
- coronary artery disease
- percutaneous coronary intervention
- metabolic syndrome
- patient reported outcomes